Novo Nordisk Rebounds as Wegovy Pill Sales Exceed Expectations

Novo Nordisk raised its full-year guidance after reporting better-than-expected demand for its Wegovy weight-loss pill during the first quarter of 2026. The strong performance sent the company’s shares sharply higher, signaling renewed optimism around its position in the highly competitive obesity drug market. 

The company reported robust revenue growth for the quarter, with overall sales increasing significantly alongside a sharp rise in operating profit. While adjusted figures were impacted by accounting-related factors tied to the U.S. healthcare system, the market’s focus remained firmly on the rapid adoption of the oral Wegovy treatment. 

This marked the first full quarter reflecting U.S. sales of the Wegovy pill, and the numbers surprised analysts. Sales more than doubled consensus expectations, while prescription volume reached approximately 1.3 million within just three months. The result reinforced the view that oral weight-loss drugs could dramatically expand the addressable market by attracting patients reluctant to use injections. 

Novo Nordisk’s leadership emphasized that the pill is not replacing injectable treatments but instead complementing them. According to CEO Mike Doustdar, both delivery methods are seeing strong demand, creating what he described as a synergistic effect rather than internal competition between products.
 
The company also maintained strong momentum for its injectable Wegovy product, though sales came in slightly below expectations. Meanwhile, diabetes treatment Ozempic saw softer sales performance year-over-year but still exceeded analyst forecasts. Combined, Novo’s obesity-care business continued to show substantial growth, underscoring the sustained demand for GLP-1 therapies worldwide. 

Competition in the obesity drug market remains fierce. Novo Nordisk and Eli Lilly are locked in a battle for dominance in a sector that analysts expect could surpass $100 billion by the end of the decade. Lilly has recently gained ground in the U.S. injectable market and launched its own oral obesity treatment, Foundayo, earlier this year. 

However, Novo appears to have gained an early advantage in the oral segment. Analysts and investors have praised the launch of the Wegovy pill as one of the strongest pharmaceutical rollouts in recent years. Early prescription data indicates significantly faster adoption compared with Lilly’s competing product, partly because Wegovy already benefits from strong brand recognition built through its injectable version. 

The strong quarter provides relief for Novo Nordisk after a challenging period marked by disappointing trial outcomes and concerns about its next-generation obesity pipeline. Investors had questioned the company’s long-term competitive position following setbacks tied to experimental treatments such as CagriSema. The recent success of the Wegovy pill now helps stabilize sentiment around the company’s future growth prospects. 

Despite the positive reaction, some analysts remain cautious. Market observers noted that Novo’s updated guidance was still relatively conservative, suggesting management may be preparing for continued competitive pressure and uncertainty around long-term prescription trends. 

Still, the latest results highlight a major shift underway in the pharmaceutical industry. Oral GLP-1 treatments are emerging as a new frontier in obesity care, with the potential to transform accessibility, patient adoption, and market scale. For now, Novo Nordisk has regained momentum — but the rivalry with Eli Lilly is only beginning to intensify.